Recent

% | $
Quotes you view appear here for quick access.

SAVIENT PHARM INC Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • iamdeebo831 iamdeebo831 Nov 28, 2012 1:46 PM Flag

    The CTO filed is the biggest news we've had yet...

    CT ORDER SAVIENT PHARMACEUTICALS INC 11/19/12
    CT ORDER SAVIENT PHARMACEUTICALS INC 11/13/12
    CT ORDER SAVIENT PHARMACEUTICALS INC 09/28/10
    CT ORDER SAVIENT PHARMACEUTICALS INC 04/01/09
    CT ORDER SAVIENT PHARMACEUTICALS INC 12/01/08

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    November 13, 2012
    ORDER GRANTING CONFIDENTIAL TREATMENT
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Savient Pharmaceuticals, Inc.
    File No. 001-15313 - CF#28610
    _____________________
    Savient Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on July 13, 2012.
    Based on representations by Savient Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:
    Exhibit 10.1 through July 9, 2014
    For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
    Craig E. Slivka
    Special Counsel

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    November 13, 2012
    ORDER GRANTING CONFIDENTIAL TREATMENT
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Savient Pharmaceuticals, Inc.
    File No. 001-15313 - CF#28610
    _____________________
    Savient Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on July 13, 2012.
    Based on representations by Savient Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:
    Exhibit 10.1 through July 9, 2014
    For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
    Craig E. Slivka
    Special Counsel

 
SVNTQ
0.00190.0000(0.00%)May 30 3:56 PMEDT